Close menu




November 13th, 2020 | 12:48 CET

EXMceuticals, KWS Saat, Nokia: Talk about crashes and comebacks

  • Investments
Photo credits: pixabay.com

When the EXMceuticals share was quoted above the 1 EUR mark last summer, the sky hung full of violins for cannabis investors. In North America, the active ingredient was largely liberalized, and in other regions of the world, too, it seemed that cannabis would soon become a medical substance like many others. But at least the hype has died down on the stock market. In the meantime, EXMceuticals shares are trading at just EUR 0.12. What has happened?

time to read: 3 minutes | Author: Nico Popp
ISIN: CA30207T1049 , DE0007074007 , FI0009000681

Table of contents:


    EXMceuticals: Cannabis Play is about to start in Europe

    More than a year ago, the Company focused on the cultivation and production of cannabis in Africa. Now, EXMceuticals has set its sights on a regulated market and operates in Portugal. Here, the Company has a processing plant for the extraction of active ingredients from cannabis plants. The focus here is on medical applications. EXMceuticals is confident that future growth will not be in the area of pure raw materials but in processed products. However, to produce pastilles, creams or even cookies, it must be possible to supply them with the desired active ingredient in exact doses. This requires the prior processing of the raw material, cannabis.

    In Germany, medical cannabis has been liberalized since 2017. Other European countries also tolerate private use as a luxury food. EXMceuticals considers itself well-positioned in case of further market liberalization in Europe and emphasizes its focus on the processing of cannabis. While pure cultivation is not a challenge, the extraction of the active ingredients is essential. Here the Company scores with a certified processing plant according to pharmacological standards.

    Furthermore, the Company already has agreements with European companies to be able to start the activities quickly. Currently, EXMceuticals is waiting for credit approval from Portuguese banks to be able to advance the business further. Other Portuguese investors have already shown interest. The share currently seems to be at rock bottom, but further liberalization trends within the less competitive European cannabis market, as well as additional financing commitments, could revive the speculative value.

    After a rollercoaster ride Profiteer of climate change: KWS Saat

    KWS Saat is a stock that has also seen ups and downs. More than ten years ago, when demography and the rise of more inferior population groups in emerging markets was an investment topic, many investors rushed to fertilizer and seed manufacturers. A veritable hype arose. During the financial crisis, many expectations came back, down to earth. But KWS Saat shares fought their way back up again. Today, the Company is mainly active in Europe and the USA and makes money with both cereals and vegetables. A new megatrend is also attracting shareholders: Climate change is changing cultivation conditions in many regions and even leading to failed harvests. With the help of specialized seeds, farmers can meet these challenges.

    Looking ahead to the current fiscal year, the Company expects growth of between 8% and 12%. The margin should also be very respectable at 11% to 13%. With this positioning, the Company is in demand on the stock market. Although a return of only 5.8% can be achieved on a one-year horizon, the share took off in the first half of the year and made a return of more than 50% within a few weeks. The dividend also shows that the value is a solid investment, with the dividend yield at around 1%.

    Nokia: With luck, the 5G hype is entirely on target

    Nokia also shows that a crash on the stock market does not have to be the end. For more than a decade, the Finnish Company was the best-known cell phone manufacturer in the world. But then came the iPhone and then the Android smartphones. The Finns missed this train, and the stock even staggered into the range around one Euro. But with the sale of the cell phone division, the Company succeeded in making a liberating move. Nokia is now a network supplier. Although there are always critical voices because the competition from China is cheaper, trade wars and protectionism could lead to Chinese manufacturers being left out in Europe and the USA in connection with 5G technology, as has already happened in some cases. The Company has achieved a turnaround and even boasts a good equity ratio. With a bit of luck, the 5G boom will have a full impact on Nokia's business.

    Fallen angels offer chances

    The history of the stock market is full of setbacks of former favourites and subsequent recoveries. Sometimes it even takes a while until the market rediscovers these fallen angels. For shareholders who look closely, this can be an opportunity. But sometimes, as a shareholder, you also need patience. Shares that have already been through a hype often find it incredibly challenging to get back on the market.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read